Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR260301 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A Monotherapy | EXPERIMENTAL | Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose |
| Part B Combination | EXPERIMENTAL | Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination |
| Name | Type | Description |
|---|---|---|
| SAR260301 | DRUG | Pharmaceutical form: film-coated tablets Route of administration: oral |
| Vemurafenib | DRUG | Pharmaceutical form: film-coated tablets Route of administration: oral |
Inclusion criteria : * Age ≥18 years old * Locally advanced or metastatic solid tumor disease as well as lymphoma for which no alternative therapy is available (Part A) * Unresectable / metastatic BRAF-mutated melanomas, progressing on BRAF inhibitor after no more than 4 months treatment or with on...
SAR260301 is an investigational small molecule being studied for the treatment of Neoplasm Malignant, a type of cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved for any use. The drug is being evaluated in patients with various advanced cancers.
SAR260301 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
SAR260301 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials according to available data.
SAR260301 has been studied in one clinical trial, identified as NCT01673737. This was a Phase I/Ib trial evaluating SAR260301 as a monotherapy or in combination with vemurafenib in patients with various advanced cancers. The trial was completed and enrolled 75 participants.
No alternative names for SAR260301 have been identified. It is a unique investigational compound developed by Sanofi. In clinical trials, it has been studied both alone and in combination with vemurafenib, but it is not known to be the same as any other marketed drug.